ArticleDiscover oncology2026
IER3 as an RFX5 transcriptional co-activator promotes hepatocellular carcinoma progression via AKR1B10-mediated p53 transcriptional regulation.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RFX5 in cancer: context-dependent molecular functions and emerging translational relevance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionHepatocellular carcinoma (HCC) exhibits profound molecular heterogeneity, which complicates prognosis and therapy. Identifying key molecular subtypes and their driving oncogenes is crucial for developing targeted strategies. This study aimed to delineate chemokine-based HCC subtypes and investigate the functional role and mechanism of a critical identified driver, Immediate Early Response 3 (IER3).
methodsBioinformatic analysis of public datasets was performed for molecular subtyping, differential expression, survival, and pathway enrichment. Clinical relevance was validated via immunohistochemistry on a tissue microarray containing 48 paired HCC/adjacent tissues. In vitro functional assays (CCK-8, colony formation, flow cytometry, wound healing, and Transwell) were conducted in SMMC-7721 cells following siRNA-mediated knockdown. Mechanistic studies employed dual-luciferase reporter, co-immunoprecipitation, qPCR, and western blot to delineate the IER3/RFX5/AKR1B10/p53 axis.
resultsUnsupervised clustering based on chemokine expression stratified HCC into two subtypes: an immune-active subtype (Cluster 1) enriched in interferon-γ signaling and a matrix-remodeling subtype (Cluster 2). Prognostic analysis further refined three patient clusters, with the aggressive Subtype C exhibiting worst survival (HR = 3.78, p < 0.001) and significant IER3 upregulation. Clinical samples confirmed IER3 protein overexpression correlated with advanced grade (p < 0.001). In vitro, IER3 knockdown suppressed proliferation, colony formation, migration/invasion, and induced apoptosis. Mechanistically, IER3 functioned as a transcriptional coactivator for RFX5, forming a complex that upregulated AKR1B10, which subsequently mediated the suppression of the tumor suppressor p53.
conclusionThis study defines a chemokine-based duality in HCC and identifies IER3 as a key driver of the aggressive subtype. Our findings indicate that IER3 contributes to HCC malignancy through the novel IER3/RFX5-AKR1B10-p53 axis in vitro, positioning it as a potential therapeutic target warranting further in vivo investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.